---
title: "Psilocybin (COMP360) in Treatment-resistant depression: Natural history, survival, and mortality"
description: "Formulary evidence on Psilocybin (COMP360) in Treatment-resistant depression: Natural history, survival, and mortality. Topics: Course: relapse and recovery in medium- to long-term outcome studies; Course: relapse by number of treatment steps, Sequenced Treatment Alternatives to Relieve Depression trial; Course: two-year outcomes under treatment as usual; Course: episode duration in US commercial claims; 9 further topics. 13 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description/natural-history-survival-and-mortality"
published: "2026-11-18T10:42:20-05:00"
modified: "2026-11-18T10:42:20-05:00"
---

# Psilocybin (COMP360) in Treatment-resistant depression: Natural history, survival, and mortality

<a id="heading-2.2.1.3"></a>

## 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

### Course: relapse and recovery in medium- to long-term outcome studies

> “We identified nine outcome studies with a total of 1279 participants and follow-up duration of between 1 and 10 years. In the short term, TRD was highly recurrent with as many as 80% of those requiring multiple treatments relapsing within a year of achieving remission. For those with a more protracted illness, the probability of recovery within 10 years was about 40%. TRD was also associated with poorer quality of life and increased mortality.”

Source: [Fekadu et al. (2009a)](https://pubmed.ncbi.nlm.nih.gov/19007996/)

<a id="topic-2.2.1.3-2"></a>

### Course: relapse by number of treatment steps, Sequenced Treatment Alternatives to Relieve Depression trial

> “Overall, those who required more treatment steps had higher relapse rates during the naturalistic follow-up phase.”
> “When more treatment steps are required, lower acute remission rates (especially in the third and fourth treatment steps) and higher relapse rates during the follow-up phase are to be expected.”

Source: [Rush et al. (2006b)](https://pubmed.ncbi.nlm.nih.gov/17074942/)

<a id="topic-2.2.1.3-3"></a>

### Course: two-year outcomes under treatment as usual

> “The 12- and 24-month IDS-SR-30 response rates were 11.6% (13/112) and 18.4% (19/103), respectively. Of the 13 responders at 12 months, only 5 were responders at 24 months. The 12- and 24-month IDS-SR-30 remission rates were 3.6% (4/112) and 7.8% (8/103), respectively. Only 1 of the 4 12-month remitters was also a remitter at 24 months.”
> “Despite the wide range of treatment options available for depression, the response rates, remission rates, and quality-of-life results in this study show that most patients with a substantial degree of treatment resistance continue to have significant symptomatology and functional disability when receiving TAU.”

Source: [Dunner et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16841617/)

<a id="topic-2.2.1.3-4"></a>

### Course: episode duration in US commercial claims

> “The mean duration of a TRD episode was 1,004 days (vs. 452 days for a non-TRD episode).”

Source: [Kubitz et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3799999/)

<a id="topic-2.2.1.3-5"></a>

### Course: time between treatment trials in the Stockholm cohort

> “Median time from start of the first antidepressant treatment to start of the second, and from start of the second antidepressant treatment to start of the third, was 165 and 197 days, respectively.”
> “Episode duration was longer in the TRD group than in the non-TRD group”

Source: [Lundberg et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9856735/)

<a id="topic-2.2.1.3-6"></a>

### All-cause mortality: US commercial claims

> “TRD was associated with a significantly higher mortality compared with non-TRD MDD (adjusted HR: 1.29; 95% CI 1.22–1.38; p < 0.0001). Survival time was significantly shorter in the TRD cohort compared with the non-TRD MDD cohort (p < 0.0001).”

Source: [Li et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6771113/)

<a id="topic-2.2.1.3-7"></a>

### All-cause and external-cause mortality: Swedish national registers

> “Adjusted HR for all-cause mortality was 1.35 (95% CI 1.21-1.50). Mortality from external causes (including suicides and accidents) was markedly higher in TRD patients than in other depressed patients (HR 1.97; 1.69-2.29), while mortality from non-external causes was similar. The adjusted EMRR was 1.52 (1.31-1.76), highest among patients 18-29 years old (EMRR 2.03; 1.31-1.76) and patients without somatic comorbidity (EMRR 1.99; 1.63-2.43).”

Source: [Reutfors et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29966932/)

<a id="topic-2.2.1.3-8"></a>

### All-cause mortality: Stockholm MDD cohort

> “The all-cause mortality rate for patients with MDD with TRD episodes was 10.7/1000 person-years at risk, compared with 8.7/1000 person-years at risk for patients with MDD without TRD episodes (hazard ratio, 1.23; 95% CI, 1.07-1.41).”

Source: [Lundberg et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9856735/)

<a id="topic-2.2.1.3-9"></a>

### Excess deaths: Swedish national registers

> “Compared with the mortality risk of other depressed patients, patients with TRD experienced excess deaths in most age and comorbidity categories in the range of 7–16 deaths per 1000 patients during 5 years. Highest numbers for all-cause excess deaths were found among patients 18–29 years old with CCI 1, where 16 [95% confidence interval 5–28] of the expected 37 [25–48] deaths per 1000 patients were excess deaths. The majority of the excess deaths were due to external causes.”

Source: [Brenner et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8047832/)

<a id="topic-2.2.1.3-10"></a>

### Suicide mortality: US commercial and Medicare claims linked to the National Death Index

> “For the 139,753 TRD, 85,602 MDD+SI/SA, and 572,098 MDD alone cohort patients, mean age ranged from 55 to 59 years and the majority were female.”
> “Suicide‐mortality rates in the three cohorts were 0.14/100 person‐years for TRD, 0.27/100 person‐years for MDD+SI/SA, and 0.04/100 person‐years for MDD alone.”

Source: [Kern et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10454258/)

> “Patients with TRD have a greater than 3-fold risk of death by suicide than patients with non-TRD MDD.”

Source: [ICER draft scope (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_TRD_Draft-Scope_For-Publication_102126-1.pdf)

<a id="topic-2.2.1.3-11"></a>

### Suicide and suicide attempts: meta-analysis of TRD samples after treatment initiation

> “Thirty percent of patients with treatment-resistant depression (TRD) attempt suicide at least once during their lifetime.”
> “The overall incidence of completed suicides was 0.47 per 100 patient years (95% CI: 0.22-1.00), and of attempted suicides 4.66 per 100 patient years (95% CI: 3.53-6.23). No differences were found in incidences following DBS, VNS or ECT.”

Source: [Bergfeld et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29665520/)

<a id="topic-2.2.1.3-12"></a>

### Suicide and suicide attempts: risk factors in Swedish national registers

> “In all, 178 patients died by suicide and 1,242 experienced a suicide attempt during follow-up.”
> “History of suicide attempts, especially if <1 year after the attempt, was a significant independent risk factor for suicide (adjusted odds ratio [aOR], 8.9; 95% confidence interval [CI], 5.1-15.7) as were 10 to 12 years of education compared to lower education (aOR, 1.69; 95% CI, 1.02-2.81).”

Source: [Reutfors et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/31774374/)

<a id="topic-2.2.1.3-13"></a>

### Intentional self-harm: Stockholm MDD cohort

> “Intentional self-harm was more than 4 times more common in TRD episodes.”

Source: [Lundberg et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9856735/)

## Related pages
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Terms and abbreviations](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations.md)
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Product information and disease description](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Clinical evidence](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Economic information and modeling report](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: References](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references.md)
